- ADC Therapeutics' confirmatory data for Zynlonta muddied by death ratesADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...Endpoints · 1mo ago↗ source
- ADC biotech Ona Therapeutics secures $86.6M in Series B raiseBarcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic. CEO Valerie Vanhooren told Endpoints News in an interview that the cas…Endpoints · 1mo ago↗ source
- A Spanish biotech banks $87M to make differentiated ADCs<figure><div><img src="https://imgproxy.divecdn.com/BSrwpN_TCQ9s_G6VqustJVQZXqRe4AvLiM4K23K7XDc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNzE1OTEyNzcxLmpwZ…